Novo Nordisk's stock experienced a sharp 13% decline after its obesity drug CagriSema underperformed in clinical trials against Eli Lilly's competitor. Compounding this setback, Novo faces intensifying competition in the GLP-1 market, where Lilly has increased its market share to 60%, while Novo has dropped to 39%. Additionally, Novo has filed a patent lawsuit against Hims & Hers Health, and despite securing EU approval for a higher dose of Wegovy, the company encounters significant pricing challenges as it navigates a crowded and price-sensitive market.
“Novo's stock falls as obesity drug falls short against Lilly's in trial. Novo Nordisk (NVO) stock san 13% before the bell on Monday after its next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial.”
“Yes, and it's been, you know, a little bit in the headlines with what happened with Hims and then of course other companies like uh Viking therapeutics now talking about a pill. Um so there's competition.”
“It just might be in a long period of consolidation. um but overall, I we're still very long-term bullish.”
“On Feb. 9, Big Pharma mainstay and GLP-1-agnostic manufacturer Novo Nordisk filed a lawsuit against Hims & Hers Health, accusing the company of unlawfully mass-marketing unapproved versions of its FDA-approved semaglutide medicines, deceiving patients, and putting their health at risk.”
“According to the suit, Novo Nordisk is aiming to 'defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetes,' while asking the court to permanently ban Hims & Hers from selling unapproved, compounded drugs that infringe on its patents.”
“Drugmakers Novo Nordisk and Eli Lilly are battling it out in the GLP-1 weight loss market. The pill version of Novo Nordisk's Ozempic has reignited competition between these two fierce rivals.”
“Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira, both of whom have pharmaceutical industry experience, for its board.”
“Helena Saxon, who has a financial background, has also been nominated.”
“Novo Nordisk had earlier acquired Prothena’s clinical-stage antibody, Coramitug...NVO is evaluating the candidate under a late-stage CLEOPATTRA study for ATTR-CM.”
“The Annual General Meeting will be held on Thursday 26 March 2026 at 14:00 (CET). The Annual General Meeting will be held as a combined physical and virtual meeting.”
“Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.”
“Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries.”
